title: Oral fluoropyrimidines may not reduce the risk of postoperative recurrence in colorectal cancer associated with mesenteric lymph node metastasis.
abstract: To clarify the efficacy and problems of postoperative adjuvant chemotherapy using oral fluoropyrimidines, the clinicopathological data of 307 colorectal cancer patients treated with or without postoperative chemotherapy were analyzed retrospectively. Patients in the chemotherapy group (n=188) who underwent curative resection were followed by administration of oral fluoropyrimidine. The other 119 patients underwent surgery alone. The disease-free survival rates were compared between the two groups. The disease-free survival rate in the chemotherapy group was significantly higher than that in the surgery alone. However, no significant difference in disease-free survival rate was found for those with tumors that were associated with mesenteric lymph node involvement and tumors with a high grade of lymphatic invasion or high grade of venous invasion. Postoperative adjuvant chemotherapy using oral fluoropyrimidines such as UFT (litegafur +4:uracil) and 5'-DFUR (doxifluridine) might not reduce the risk of recurrence in colorectal cancer with mesenteric lymph nodes involvement.
authors.affiliation: Department of Surgery, Kurume University School of Medicine, Fukuoka, Japan. yogata@med.kurume-u.ac.jp
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Ogata
authors.forename: Shojiro
authors.initials: S
authors.lastname: Torigoe
authors.forename: Keiko
authors.initials: K
authors.lastname: Matono
authors.forename: Teruo
authors.initials: T
authors.lastname: Sasatomi
authors.forename: Nobuya
authors.initials: N
authors.lastname: Ishibashi
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Shida
authors.forename: Akira
authors.initials: A
authors.lastname: Ohkita
authors.forename: Takamasa
authors.initials: T
authors.lastname: Fukumitu
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Mizobe
authors.forename: Satoru
authors.initials: S
authors.lastname: Ikeda
authors.forename: Shujiro
authors.initials: S
authors.lastname: Ogo
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ozasa
authors.forename: Kazuo
authors.initials: K
authors.lastname: Shirouzu
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D003082:Colectomy; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage*; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008643:Mesentery; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D005467:Floxuridine; D005641:Tegafur; D014498:Uracil; C025034:doxifluridine